Clinical-stage biopharmaceutical company developing biologic therapies for serious, vision-threatening eye diseases
Clinical-stage biopharmaceutical company developing biologic therapies for serious, vision-threatening eye diseases. Its lead candidate OLN324 is a VEGF/Ang2 bispecific antibody for diabetic macular edema and wet age-related macular degeneration; OLN102 is a bispecific antibody program for thyroid eye disease.